Perspective Therapeutics Inc [AMEX: CATX] plunged by -$3.17 during the normal trading session on while it closed the day at $3.00.
Perspective Therapeutics Inc stock has also loss -66.37% of its value over the past 7 days. However, CATX stock has declined by -80.88% in the 3 months of the year. Over the past six months meanwhile, it has lost -80.13% and lost -25.37% year-on date.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for CATX stock reached $202.76 million, with 67.59 million shares outstanding and 48.99 million shares in the current float. Compared to the average trading volume of 951.48K shares, CATX reached a trading volume of 12586012 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Perspective Therapeutics Inc [CATX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CATX shares is $20.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CATX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Perspective Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 24, 2024. While these analysts kept the previous recommendation, Wedbush raised their target price to Outperform. The new note on the price target was released on October 01, 2024, representing the official price target for Perspective Therapeutics Inc stock. Previously, the target price had yet another raise to $21, while Truist analysts kept a Buy rating on CATX stock.
The Average True Range (ATR) for Perspective Therapeutics Inc is set at 0.98, with the Price to Sales ratio for CATX stock in the period of the last 12 months amounting to 22.94. The Price to Book ratio for the last quarter was 0.62, with the Price to Cash per share for the same quarter was set at 3.96.
CATX stock trade performance evaluation
Perspective Therapeutics Inc [CATX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -66.37. With this latest performance, CATX shares dropped by -74.34% in over the last four-week period, additionally sinking by -80.13% over the last 6 months – not to mention a rise of 16.19% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CATX stock in for the last two-week period is set at 9.64, with the RSI for the last a single of trading hit 4.60, and the three-weeks RSI is set at 15.18 for Perspective Therapeutics Inc [CATX]. The present Moving Average for the last 50 days of trading for this stock 11.75, while it was recorded at 6.16 for the last single week of trading, and 12.76 for the last 200 days.
Perspective Therapeutics Inc [CATX]: An insightful look at the core fundamentals
Perspective Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.60 and a Current Ratio set at 9.60.
Earnings per share (EPS) analysis for Perspective Therapeutics Inc [CATX] stock
With the latest financial reports released by the company, Perspective Therapeutics Inc posted -0.9/share EPS, while the average EPS was predicted by analysts to be reported at -0.4/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.5. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CATX.
Perspective Therapeutics Inc [CATX]: Institutional Ownership
There are presently around $81.42%, or 102.32%% of CATX stock, in the hands of institutional investors.
